A study presented by researchers at Fox Chase Cancer Center shows that some patients with metastatic kidney cancer receiving a combination therapy can safely stop or pause treatment after two years if they have a good response.
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage 3 or 4 clear cell renal cell carcinoma generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to the Vanderbilt University Medical Center study published in JCO Precision Oncology.
The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.
Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.